NAFAZAIR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nafazair, and what generic alternatives are available?
Nafazair is a drug marketed by Bausch And Lomb and Pharmafair and is included in two NDAs.
The generic ingredient in NAFAZAIR is naphazoline hydrochloride. There are eight drug master file entries for this compound. Additional details are available on the naphazoline hydrochloride profile page.
Summary for NAFAZAIR
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 91 |
Patent Applications: | 3,032 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NAFAZAIR at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for NAFAZAIR
US Patents and Regulatory Information for NAFAZAIR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb | NAFAZAIR | naphazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 040073-001 | May 25, 1994 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pharmafair | NAFAZAIR | naphazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 088101-001 | Apr 15, 1983 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |